An interventional study of Community-based supervised remote cardiac rehabilitation and Home-based cardiac rehabilitation program in Congenital Heart Disease (CHD), Complex Congenital Heart Disease and Congenital Heart Disease in Children, sponsored by Seoul National University Hospital. Not yet recruiting at 1 site in Korea, Republic of. Open to participants aged 8 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-04-04.
Sponsored by Seoul National University Hospital · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Heart Defects, Congenital with a site in Korea, Republic of — 2 open to participants now, 2 under way, none of them phase 3. Heart Defects, Congenital · Korea, Republic of.
Among the 17 studies in Heart Defects, Congenital with a site in Korea, Republic of, this one is the only one that started in 2025, is one of 8 with no phase, and was the 17th registered.
992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.
Browse Heart Defects, Congenital studies →2 of the 17 studies in Heart Defects, Congenital with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Pusan National University Yangsan Hospital · Sites in Korea, Republic of
Ages up to 2
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.
This study: 8 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10 is below the median of 60 across 508 interventional studies indexed under Heart Defects, Congenital.
Median enrollment 36 across the 9 interventional studies, 310 across the 8 observational. Of the 14 that completed or were terminated, 1 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 17 have an industry lead sponsor. The 7 most frequent:
Seoul National University Hospital is the lead sponsor of 1,903 studies on the registry; 276 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.
Seoul National University Hospital has 7 studies filed under Heart Defects, Congenital — fewer than ten, so there is no comparison to draw.
1 of the studies in Heart Defects, Congenital with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06041685Pusan National University Yangsan HospitalEffect of Local Warming for Arterial Catheterization in Pediatric Anesthesia | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies in Heart Defects, Congenital with a site in Korea, Republic of, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is to develop a 12-week community-based remote cardiac rehabilitation program for pediatric patients with complex congenital heart disease and to assess its validity and safety.
For these children, a multidisciplinary approach including pediatric rehabilitation medicine, pediatric thoracic surgery, pediatrics, pediatric psychiatry, sports science, and nutrition is essential, but such comprehensive services are rarely available in Korea. As a result, pediatric cardiac rehabilitation at the community level is nearly nonexistent. Recent long-term retrospective cohort studies suggest that maintaining regular physical activity and aerobic capacity from early childhood significantly reduces future cardiovascular complications, emphasizing the importance of early pediatric cardiac rehabilitation. However, participation in existing programs is low due to limited accessibility.
The investigators hypothesize that a community-based remote cardiac rehabilitation program for these patients is both valid and safe. Participants will be children aged 8-18 years diagnosed with complex congenital heart disease , at least 3 months post-surgery, and stable cardiovascular status.
Interventions include supervised and self-directed cardiac rehabilitation exercises. Monitoring (heart rate, SpO2, ECG) will be performed in real-time, with non-real-time data collection of physical activity using smartwatches. The intervention lasts 12 weeks with a 12-week follow-up.
Validity measures include baseline evaluation, adherence, dropout rate, participant and parent satisfaction, and changes in cardiopulmonary exercise capacity, physical activity, body composition, fitness (6-minute walk, strength, flexibility, respiratory muscle strength), and questionnaires (physical activity, quality of life, exercise satisfaction, depression, psychological state).
Safety will be assessed by monitoring adverse events, vital signs, fatigue (Borg scale), and pain before and after exercise.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The group is provided with a single session of supervised remote cardiac rehabilitation session per week, and 4 sessions of home-based rehabilitation. During the supervised remote session, the EKG signal, heart rate and SpO2 of the participants are monitored in real-time using a single lead EKG and SpO2 monitor. Their activity levels are also recorded using a smartwatch, in number of steps and minutes in moderate-vigorous physical activity time
Other: Community-based supervised remote cardiac rehabilitation · Other: Home-based cardiac rehabilitation program
Community-based supervised remote cardiac rehabilitation begins with a weekly session led by exercise specialists, who use remote-based materials to match each participant's target heart rate and rate of perceived exertion (RPE). During these sessions, participants perform aerobic, strength, and respiratory exercises using progressive overload principles, with devices such as the POWERbreathe Plus supporting individualized respiratory training. Depending on the risk classification for each participant, they will be provided with different intensity of exercises (depending on their measured HR max, HRR, and/or RPE).
Beyond the single supervised session, participants undertake four weekly home-based sessions. * Low-Risk Group: Aerobic and respiratory exercises are performed four times per week, plus strength training once or twice weekly. Each 60-minute session includes a 10-minute warm-up, 40-minute main exercise, and 10-minute cool-down. Indoor sessions use remote exercise content and respiratory training devices, while outdoor activities may involve walking, jogging, cycling, or swimming. Exercises progress in duration, intensity, and resistance. * Moderate-Risk Group: Aerobic and respiratory exercises are done four times per week with an RPE of 8-13. Intensity and duration increase gradually, contingent on symptom stability and improved endurance. * High-Risk Group: Aerobic and respiratory sessions occur four times a week at an RPE of 8-10, each lasting around 30 minutes (5-minute warm-up, 20-30-minute main exercise, 5-minute cool-down).
Drop-out rate
Time frame: baseline, 12 weeks after, 24 weeks after follow-up
Attendance rate
Time frame: baseline, 12 weeks after, 24 weeks after follow-up
oxygen consumption, VO2
Oxygen consumption (VO2) refers to the rate at which the body takes in and uses oxygen.
Time frame: baseline, 12 weeks after, 24 weeks after follow-up
maximal oxygen consumption, VO2 max
Maximal oxygen consumption (VO2 max) represents the highest rate at which an individual can take in, transport, and utilize oxygen during maximal or exhaustive exercise.
Time frame: baseline, 12 weeks after, 24 weeks after follow-up
Respiratory exchange rate, RER
Respiratory Exchange Ratio (RER) is the ratio of the volume of carbon dioxide produced (VCO2) to the volume of oxygen consumed (VO2) in the body. RER = VCO2 / VO2
Time frame: baseline, 12 weeks after, 24 weeks after follow-up
minute ventilation (VE)
minute ventilation (VE) refers to the total volume of air inhaled or exhaled by an individual per minute. VE = Tidal Volume (VT) x Respiratory Rate (RR)
Time frame: baseline, 12 weeks after, 24 weeks after follow-up
ventilation effectiveness, VE/VO2
Ventilation effectiveness, when expressed as the ratio of minute ventilation (VE) to oxygen consumption (VO2) (VE/VO2), represents the volume of air that needs to be breathed to consume one liter of oxygen.
Time frame: baseline, 12 weeks after, 24 weeks after follow-up
oxygen per pulse, O2 pulse
Time frame: baseline, 12 weeks after, 24 weeks after follow-up
oxygen saturation, SpO2
Time frame: baseline, 12 weeks after, 24 weeks after follow-up
maximal heart rate during exercise, HR max
Time frame: baseline, 12 weeks after, 24 weeks after follow-up
heart rate by exercise intensity
Time frame: baseline, 12 weeks after, 24 weeks after follow-up
average number of steps for 7 days using smartwatch
Time frame: baseline, 12 weeks after, 24 weeks after follow-up
average moderate-vigorous physical activity time for 7days using smartwatch, minutes
Time frame: baseline, 12 weeks after, 24 weeks after follow-up
skeletal muscle mass (kg)
Time frame: baseline, 12 weeks after, 24 weeks after follow-up
body fat mass (kg)
Time frame: baseline, 12 weeks after, 24 weeks after follow-up
body fat percentage
Time frame: baseline, 12 weeks after, 24 weeks after follow-up
Abdominal fat percentage
Time frame: baseline, 12 weeks after, 24 weeks after follow-up
Intracellular moisture, extracellular moisture
Time frame: baseline, 12 weeks after, 24 weeks after follow-up
Radial artery pulse wave amplification index: Augmentation index (AIx@75 index)
arterial stiffness and wave reflection at a heart rate of 75 beats per minute
Time frame: baseline, 12 weeks after, 24 weeks after follow-up
Carotid-femoral pulse wave velocity, c-f PWV
Carotid-femoral pulse wave velocity (c-f PWV) is a non-invasive medical test used to assess arterial stiffness, which is a measure of how rigid or flexible the arteries are. c-f PWV = Distance between carotid and femoral sites / Time difference between pulse wave arrival at the two sites.
Time frame: baseline, 12 weeks after, 24 weeks after follow-up
Flow-mediated dilation, FMD%
Flow-Mediated Dilation (FMD%) is a non-invasive ultrasound technique used to assess endothelial function, which is the ability of the inner lining of arteries (the endothelium) to relax and contract properly. FMD% specifically measures the percentage change in the diameter of an artery in response to an increase in blood flow
Time frame: baseline, 12 weeks after, 24 weeks after follow-up
6 minutes walk test
total distance in meters
Time frame: baseline, 12 weeks after, 24 weeks after follow-up
lower limb muscle strength test (peak torque/BW)
Time frame: baseline, 12 weeks after, 24 weeks after follow-up
Upper extremity strength test: grip force (kg)
Time frame: baseline, 12 weeks after, 24 weeks after follow-up
Flexibility check: Flexibility distance (cm)
Time frame: baseline, 12 weeks after, 24 weeks after follow-up
Respiratory muscle strength test (MIP mmH2O)
Maximal Inspiratory Pressure (MIP) is a measurement in assessing the strength of inspiratory muscles. It reflects the strength of the diaphragm and other inspiratory muscles.
Time frame: baseline, 12 weeks after, 24 weeks after follow-up
Global Physical Activity Questionnaire
The Global Physical Activity Questionnaire (GPAQ) doesn't have a fixed minimum and maximum score. A score of 0 would indicate no reported physical activity. Higher scores means a better outcome in terms of physical activity levels.
Time frame: baseline, 12 weeks after, 24 weeks after follow-up
Pediatric Quality of Life Inventory™ (PedsQL™) for subjects and parents
Minimum Value (Total Score): 0 Maximum Value (Total Score): 100 Higher Scores Mean: A better outcome. Higher scores on the PedsQL™ indicate a better health-related quality of life, as reported by either the child/adolescent or their parent.
Time frame: baseline, 12 weeks after, 24 weeks after follow-up
Pediatric Quality of Life Inventory Cardiac, PedsQL™ Cardiac
Minimum Value (Total Score): 0 Maximum Value (Total Score): 100 Higher Scores Mean: A better outcome. Higher scores on the PedsQL™ Cardiac module indicate a better health-related quality of life for the child with a cardiac condition.
Time frame: baseline, 12 weeks after, 24 weeks after follow-up
Program satisfactory survey
Time frame: 12 weeks
Resilience Scale for Youth, RS-Y
Minimum Value: 25 Maximum Value: 125 Higher Scores Mean: A better outcome. Higher scores on the Resilience Scale for Youth indicate a higher level of resilience in the individual.
Time frame: baseline, 12 weeks after, 24 weeks after follow-up
Child Behavior Checklist for parents, CBCL
Minimum Value : 0 Maximum Value : 118 Higher Scores Mean: A worse outcome. Higher scores on the Total Problems scale of the CBCL indicate a greater number and severity of reported behavioral and emotional problems in the child.
Time frame: baseline, 12 weeks after, 24 weeks after follow-up
blood pressure by exercise intensity
Time frame: baseline, 12 weeks after, 24 weeks after follow-up
Children's Depression Inventory 2, K-CDI-2:SR
Minimum Value: 0 Maximum Value: 54 Higher Scores Mean: A worse outcome. Higher scores on the K-CDI-2:SR indicate higher levels of reported depressive symptoms.
Time frame: baseline, 12 weeks after, 24 weeks after follow-up
Revised Children's Manifest Anxiety Scale 2, RCMAS-2
Minimum Value: 0 Maximum Value: 49 Higher Scores Mean: A worse outcome. Higher scores on the RCMAS-2 indicate higher levels of reported anxiety.
Time frame: baseline, 12 weeks after, 24 weeks after follow-up
Incidence proportion of adverse events and harm during exercise
Incidence proportion of participants with exercise-related adverse events as assessed by CTCAE v4.0
Time frame: 12 weeks after, 24 weeks after follow-up
Incidence rate of adverse events and harm during exercise
Incidence rate of participants with exercise-related adverse events as assessed by CTCAE v4.0
Time frame: 12 weeks after, 24 weeks after follow-up
Changes in pre- and post-workout heart rate
Time frame: up to 12 weeks
Changes in pre- and post-workout oxygen saturation (SpO2)
Time frame: up to 12 weeks
Changes in pre- and post-workout respiratory rate
Time frame: up to 12 weeks
Rate of Perceived Exertion, Borg scale
Unabbreviated Scale Title: Rate of Perceived Exertion (RPE) Scale Minimum Value: 6 Maximum Value: 20 Higher Scores Mean: A worse outcome. Higher numbers on the Borg scale indicate a greater feeling of exertion.
Time frame: up to 12 weeks
Upper extremity strength test: relative grip force (%)
Time frame: baseline, 12 weeks after, 24 weeks after follow-up
lower limb muscle strength test (peak torque)
Time frame: baseline, 12 weeks after, 24 weeks after follow-up
extracellular moisture ratio
Time frame: baseline, 12 weeks after, 24 weeks after follow-up
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for May 2025; primary completion for Dec 2028, 43 months later.
Of 208 non-industry interventional studies with no phase under Heart Defects, Congenital, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 43 months is above that.
Counting every sponsor, half of 226 studies reached it within 34 months; a quarter within 17 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Seoul National University Hospital →